Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Iota-carrageenan  COVID-19 treatment studies for Iota-carragee..  C19 studies: Iota-carragee..  Iota-carragee..   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
 
Iota-carrageenan COVID-19 studies. Submit updates/corrections.
Dec 8
2021
Fröba et al., International Journal of Molecular Sciences, doi:10.3390/ijms222413202 (In Vitro) Iota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma and Delta
In Vitro study of iota-, lambda-, and kappa-carrageenan sulfated polysaccharides extracted from red seaweed on SARS-CoV-2 Wuhan type and variants Alpha, Beta, Gamma and Delta, showing that all three carrageenan types had antiviral activit..
Sep 7
2021
Morokutti-Kurz et al., International Journal of General Medicine, doi:10.2147/IJGM.S325861 The Saliva of Probands Sucking an Iota-Carrageenan Containing Lozenge Inhibits Viral Binding and Replication of the Most Predominant Common Cold Viruses and SARS-CoV-2
Prospective study of 31 subjects analyzing iota-carrageenan concentration in saliva after using an iota-carrageenan containing lozenge, showing sufficient concentration to neutralize common respiratory viruses including SARS-CoV-2. For SA..
Jul 26
2021
Alsaidi et al., Marine Drugs, doi:10.3390/md19080418 (In Vitro) Griffithsin and Carrageenan Combination Results in Antiviral Synergy against SARS-CoV-1 and 2 in a Pseudoviral Model
In Vitro and In Silico analysis showing SARS-CoV-2 antiviral activity of carageenan, and synergistic activity from the combination of carrageenan and griffithsin.
Jun 14
2021
Hemilä et al., Pharmacology Research and Perspectives, doi:10.1002/prp2.810 Carrageenan nasal spray may double the rate of recovery from coronavirus and influenza virus infections: Re-analysis of randomized trial data
Individual patient data meta analysis of two RCTs showing nasal iota-carrageenan improved recovery rate and shortened the duration of long colds. There was a 71% reduction in the risk of long colds (>20 days). The increase in recovery rat..
Apr 28
2021
Schütz et al., American Journal of Physiology: Lung Cellular and Molecular Physiology, doi:10.1152/ajplung.00552.2020 Carrageenan-containing over-the-counter nasal and oral sprays inhibit SARS-CoV-2 infection of airway epithelial cultures
In Vitro study showing that carrageenan-containing nose spray and mouth spray inhibit SARS-CoV-2 in human airway epithelial cultures.
Apr 27
2021
Varese et al., bioRxiv, doi:10.1101/2021.04.27.441512 (Preprint) (In Vitro) Iota-carrageenan prevents the replication of SARS-CoV-2 on an in vitro respiratory epithelium model
In Vitro Calu-3 (human respiratory epithelial cell line) study showing that iota-carrageenan inhibits SARS-CoV-2.
Apr 15
2021
Figueroa et al., International Journal of General Medicine, doi:10.2147/IJGM.S328486 (date from earlier preprint) Efficacy of a nasal spray containing Iota-Carrageenan in the prophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 disease A pragmatic multicenter, randomized, double-blind, placebo-controlled trial (CARR-COV-02)
80% fewer symptomatic cases [p=0.03]. Prophylaxis RCT with 394 healthcare workers, 196 treated with iota-carrageenan, showing significantly lower symptomatic cases with treatment. There were no deaths or hospitalizations. There was a significant number of PCR- symptomatic cas..
Feb 17
2021
Morokutti-Kurz et al., PLoS ONE, doi:10.1371/journal.pone.0237480 (In Vitro) Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro
In Vitro study showing that SARS-CoV-2 is inhibited by iota-carrageenan in a dose dependent manner and to the same extent as other respiratory viruses for which a clinical benefit has been proven. Authors note that clinical data and post ..
Jan 11
2021
Chahla et al., American Journal of Therapeutics, doi:10.1097/MJT.0000000000001433 Intensive Treatment With Ivermectin and Iota-Carrageenan as Pre-exposure Prophylaxis for COVID-19 in Health Care Workers From Tucuman, Argentina
95% fewer moderate/severe cases [p=0.002] and 84% fewer cases [p=0.004]. Prophylaxis RCT for ivermectin and iota-carrageenan in Argentina, 117 healthcare workers treated with ivermectin and iota-carrageenan, and 117 controls, showing significantly lower cases with treatment. There were no moderate/severe cases..
Dec 29
2020
Hans et al., Bioresource Technology Reports, doi:10.1016/j.biteb.2020.100623 (Review) Antiviral activity of sulfated polysaccharides from marine algae and its application in combating COVID-19: Mini review
Review of the antiviral activity of marine sulfated polysaccharides including carrageenan, and the mechanisms of action for inhibiting different stages of viral infection.
Nov 17
2020
Carvallo et al., Journal of Biomedical Research and Clinical Investigation, doi:10.31546/2633-8653.1007 Study of the Efficacy and Safety of Topical Ivermectin + Iota-Carrageenan in the Prophylaxis against COVID-19 in Health Personnel
100% fewer cases [p<0.0001]. Prophylaxis study using ivermectin and iota-carrageenan showing 0 of 788 cases from treated healthcare workers, compared to 237 of 407 control. The authors later reported that carrageenan is not necessary in this protocol . See for discu..
Aug 24
2020
Song et al., Food & Function, doi:10.1039/D0FO02017F (In Vitro) Inhibitory activities of marine sulfated polysaccharides against SARS-CoV-2
In Vitro study showing significant antiviral activity of marine sulfated polysaccharides iota-carrageenan, sea cucumber sulfated polysaccharide, and fucoidan.
Aug 21
2020
Bansal et al., PLoS ONE, doi:10.1371/journal.pone.0259943 (date from earlier preprint) (In Vitro) Iota-carrageenan and xylitol inhibit SARS-CoV-2 in Vero cell culture
In Vitro study showing that iota-carrageenan in concentrations as low as 6 µg/mL (easily achievable with existing nasal sprays) inhibits SARS-CoV-2 in Vero cell cultures.
Jun 29
2020
Sattari et al., Research Square, doi:10.21203/rs.3.rs-37994/v1 (Preprint) Repositioning Therapeutics for COVID-19: Virtual Screening of the Potent Synthetic and Natural Compounds as SARS-CoV-2 3CLpro Inhibitors
In Silico study identifying kappa-carrageenan and other compounds as potential candidates for SARS-CoV-2 inhibition.
2014
Koenighofer et al., Multidisciplinary Respiratory Medicine, doi:10.1186/2049-6958-9-57 Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials
Analysis of 2 RCTs concluding that carrageenan nasal spray reduced duration of virus-confirmed common colds, increased viral clearance, and reduced relapses.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit